Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, January 29, 2015
Technology Networks
 
Register | Sign in
Home Page > Videos > Preclinical Drug Safety: High Quality Data obtained with a New Automated Patch Clamp Platform
  Videos

Return

Preclinical Drug Safety: High Quality Data obtained with a New Automated Patch Clamp Platform
Select Biosciences Ltd

Many compounds have been reported to prolong the QT interval interfering with the hERG channel, leading to life-threatening cardiac arrhythmias. According to FDA guideline every drug going to market must be tested on the hERG channel. Due to this international regulation, there is a great demand for accurate hERG screens as well as for other pacemaker channels. Manual patch clamp is still the gold standard for investigation of ion channels, but throughput is low and a skilled operator is needed. Cytocentrics overcomes these problems by developing the CytoPatch™ Instrument. Thus outsourcing of patch clamp screening offers a true advantage to drug developing companies: Lowering their operating costs and having access to the latest technology and scientific expertise. As examples for the patch clamp quality of the CytoPatch™ Instrument we show that the electrophysiological and pharmacological properties of the cardiac potassium channels like hERG and kv1.5 investigated on the CytoPatch™ Instrument are in excellent agreement with data known from manual patch clamp: This demonstrates that ion channel screening on the CytoPatch™ Instrument delivers the same high data quality known from manual patch clamp at a throughput level required for safety pharmacology screening.

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
NIH Launches Tool to Advance Down Syndrome Research
Web portal will help approved professionals to plan clinical studies.
NIH Researchers Tackle Thorny Side of Gene Therapy
Pre-clinical studies in mice reveal ways to reduce cancer risk with modified treatment.
Early Blood Glucose Control Lengthens Life in People with Type 1 Diabetes
Reductions in diabetes complications resulting from tight glucose control translate into longer lifespans.
Oxford Vaccine Group Begins First Trial of New Ebola Vaccine
Oxford University doctors and scientists are starting the first safety trial of an experimental preventative Ebola vaccine regimen being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen).
GRP78 Protein Possible Universal Therapeutic Target
Drug combination including Viagra is effective tool in targeting the protein.
Stem Cell Transplants May Halt Progression of Multiple Sclerosis
NIH-funded study yields encouraging early results.
Novel Agent Decreases Neuropathic Pain in Patients with Type 2 Diabetes
Promising profile of disease modification and pain reduction leads to proof of concept trials.
Parkinson's Vaccine: EU-Team Launches Clinical Trial
Vaccine candidate based on proprietary technology by AFFiRiS AG.
Two Drugs are No More Effective Than One to Treat Common Kidney Disease
NIH study finds limited kidney benefit from more rigorous blood pressure treatment.
Gene Therapy Provides Safe, Long-Term Relief for Patients with Severe Hemophilia B
Gene therapy pioneered by St. Jude Children’s Research Hospital, University College London and the Royal Free Hospital provides men with hemophilia B reliable relief from the bleeding disorder.
Scroll Up
Scroll Down
SELECTBIO
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn